Advertisement

Topics

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

2018-01-16 09:55:10 | BioPortfolio

Summary

This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.

Study Design

Conditions

Human Metapneumovirus and Human Parainfluenza Infection

Intervention

mRNA-1653, Placebo

Location

Meridian Clinical Research, LLC
Omaha
Nebraska
United States
68134

Status

Recruiting

Source

Moderna Therapeutics

Results (where available)

View Results

Links

Published on BioPortfolio: 2018-01-16T09:55:10-0500

Clinical Trials [3347 Associated Clinical Trials listed on BioPortfolio]

Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults

Human metapneumovirus (HMPV) is a virus that can cause respiratory illness. In older adults, those with asthma, infants, and children, illness can be severe, but in healthy adults the viru...

Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine ...

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease. The purpose of this study is t...

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and ho...

Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

Human Parainfluenza Virus Type 1 (HPIV1) is a leading cause of viral respiratory infections in children, the elderly, and those with compromised immune systems. HPIV1 is also the leading c...

PubMed Articles [25459 Associated PubMed Articles listed on BioPortfolio]

Human Parainfluenza Virus Infection in Severe Acute Respiratory Infection Cases in Beijing, 2014-2016: a Molecular Epidemiological Study.

Severe Acute Respiratory Infection (SARI) threatens human health and even survival, causing a huge number of hospitalized patients every year. However, as one of the most common respiratory viruses ci...

Human Metapneumovirus Infection and Acute Respiratory Distress Syndrome During Pregnancy.

Human metapneumovirus has recently been recognized as an important cause of severe respiratory viral infections and of viral infections in patients admitted to intensive care units. Little is known ab...

Human parainfluenza virus surveillance in pediatric patients with lower respiratory tract infections: a special view of parainfluenza type 4.

Characterize the role of human parainfluenza virus and its clinical features in Brazilian children under 2 years of age presenting with acute lower respiratory tract infections.

Human Metapneumovirus Infection: Pneumonia Risk Factors in Solid Organ Transplantation Patients and CT findings.

Human metapneumovirus (HMPV) is a newly detected pathogen which can cause lower respiratory tract disease. Clinical characteristics, computed tomography (CT) findings, and outcomes of HMPV pneumonia i...

Human SMOOTHENED inhibits human immunodeficiency virus type 1 infection.

Human SMOOTHENED (SMO) was identified by expression cloning as a new host factor that inhibits HIV-1 infection. Forced expression of SMO inhibited HIV-1 replication and infection with a single-round l...

Medical and Biotech [MESH] Definitions

A genus of the subfamily PNEUMOVIRINAE, containing two members: Turkey rhinotracheitis virus and a human Metapneumovirus. Virions lack HEMAGGLUTININ and NEURAMINIDASE.

An acute inflammatory disease of the upper RESPIRATORY TRACT, caused by paramyxoviruses, occurring primarily in infants and young children; the viruses most commonly implicated are PARAINFLUENZA VIRUS TYPE 3; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; and METAPNEUMOVIRUS.

Vaccines or candidate vaccines used to prevent infection with parainfluenza viruses in humans and animals.

A species of RESPIROVIRUS frequently isolated from small children with pharyngitis, bronchitis, and pneumonia.

A species of RUBULAVIRUS associated particularly with acute laryngotracheitis (CROUP) in children aged 6 months to 3 years.

More From BioPortfolio on "Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults"

Quick Search
Advertisement

 

Searches Linking to this Trial